NCT06967558View on ClinicalTrials.gov

The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

October 30, 2027

Study Completion Date

March 31, 2028

Conditions
PreDiabetes
Interventions
BIOLOGICAL

Exendin 9-39

Exendin 9-39 is a competitive antagonist of the GLP-1 receptor

BIOLOGICAL

Saline

Saline

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06967558 - The Role of Islet GLP-1 in the Pathogenesis of Prediabetes | Biotech Hunter | Biotech Hunter